| Date Filed | Type | Description |
| 08/15/2023 |
4
| Castillo Kirsten (Director) has filed a Form 4 on ACV Auctions Inc.|
Txns:
| Exercised 30,000 shares
@ $0
Sold 30,000 shares
@ $15.69, valued at
$470.7k
Exercised 30,000 options to buy
@ $5.42, valued at
$162.6k
Converted 30,000 options to buy
@ $0 |
|
| 08/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
4
| Castillo Kirsten (Director) has filed a Form 4 on Ocugen, Inc.|
Txns:
| Granted 112,205 options to buy
@ $0.4581, valued at
$51.4k
|
|
| 05/26/2023 |
4
| Castillo Kirsten (Director) has filed a Form 4 on ACV Auctions Inc.|
Txns:
| Exercised 36,583 shares
@ $0
Sold 36,583 shares
@ $17.34, valued at
$634.3k
Exercised 36,583 options to buy
@ $5.42, valued at
$198.3k
Converted 36,583 options to buy
@ $0 |
|
| 05/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2021 |
4
| Castillo Kirsten (Director) has filed a Form 4 on Ocugen, Inc.|
Txns:
| Sold 15,000 shares
@ $15, valued at
$225k
|
|
| 06/09/2021 |
4
| Castillo Kirsten (Director) has filed a Form 4 on Ocugen, Inc.|
Txns:
| Sold 10,000 shares
@ $10, valued at
$100k
|
|
| 03/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/23/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 01/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/29/2020 |
4
| Castillo Kirsten (Director) has filed a Form 4 on Ocugen, Inc.|
Txns:
| Bought 75,000 shares
@ $0.3133, valued at
$23.5k
|
|
| 04/08/2020 |
4
| Castillo Kirsten (Director) has filed a Form 4 on Ocugen, Inc.|
Txns:
| Granted 54,000 options to buy
@ $0.28, valued at
$15.1k
|
|
| 04/08/2020 |
3
| Castillo Kirsten (Director) has filed a Form 3 on Ocugen, Inc. |